4.6 Article

Brca1 is expressed in human microglia and is dysregulated in human and animal model of ALS

Journal

MOLECULAR NEURODEGENERATION
Volume 10, Issue -, Pages -

Publisher

BIOMED CENTRAL LTD
DOI: 10.1186/s13024-015-0023-x

Keywords

Microglia; Transcriptomics; hSOD1(G93A) mice; ALS patients; Brca1

Categories

Funding

  1. NICHD
  2. Spanish Government [PI10/00709]
  3. Government of the Basque Country grant (Proyectos de Investigacion Sanitaria and Fondo Comun de Cooperacion Aquitania-Euskadi)
  4. Fondation pour la Recherche Medicale
  5. French Government, ANR-FNS grant, GliALS [ANR-14-CE36-0009-01]
  6. patient organisations Demain Debout Aquitaine
  7. Verticale
  8. Agence Nationale de la Recherche (ANR) [ANR-14-CE36-0009] Funding Source: Agence Nationale de la Recherche (ANR)

Ask authors/readers for more resources

Background: There is growing evidence that microglia are key players in the pathological process of amyotrophic lateral sclerosis (ALS). It is suggested that microglia have a dual role in motoneurone degeneration through the release of both neuroprotective and neurotoxic factors. Results: To identify candidate genes that may be involved in ALS pathology we have analysed at early symptomatic age (P90), the molecular signature of microglia from the lumbar region of the spinal cord of hSOD1(G93A) mice, the most widely used animal model of ALS. We first identified unique hSOD1(G93A) microglia transcriptomic profile that, in addition to more classical processes such as chemotaxis and immune response, pointed toward the potential involvement of the tumour suppressor gene breast cancer susceptibility gene 1 (Brca1). Secondly, comparison with our previous data on hSOD1(G93A) motoneurone gene profile substantiated the putative contribution of Brca1 in ALS. Finally, we established that Brca1 protein is specifically expressed in human spinal microglia and is up-regulated in ALS patients. Conclusions: Overall, our data provide new insights into the pathogenic concept of a non-cell-autonomous disease and the involvement of microglia in ALS. Importantly, the identification of Brca1 as a novel microglial marker and as possible contributor in both human and animal model of ALS may represent a valid therapeutic target. Moreover, our data points toward novel research strategies such as investigating the role of oncogenic proteins in neurodegenerative diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available